4.00Open4.00Pre Close0 Volume20 Open Interest2.50Strike Price0.00Turnover393.92%IV27.95%PremiumAug 16, 2024Expiry Date2.58Intrinsic Value100Multiplier6DDays to Expiry1.42Extrinsic Value100Contract SizeAmericanOptions Type0.9495Delta0.0399Gamma1.92Leverage Ratio-0.0213Theta0.0004Rho1.82Eff Leverage0.0007Vega
Alector Stock Discussion
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
Alector presented baseline characteristics for the INVOKE-2 Phase 2 clinical trial of AL002, a TREM2 agonist, at AAIC® 2024.
The trial, involving 381 participants with early Alzheimer's disease (AD), is the first global Phase 2 study evaluating a TREM2 agonist's safety and efficacy in slowing AD progression.
Key point...
$Alector (ALEC.US)$
$PacWest Bancorp (PACW.US)$
Who will squeeze best?
All in or just a little?
$Viasat (VSAT.US)$ +5.9% (the Wall Street Journal reported that the satellite company was close to a deal to sell a military communications unit to defense contractor $L3Harris Technologies (LHX.US)$ for nearly $2 billion.)
$Myovant Sciences (MYOV.US)$ +31.3% (the biopharmaceutical company rejected a bid by its largest shareholder, Sumitovant Biopharma, to buy the shares it doesn’t already own for $22.75 per share. Myovant said...
• $Antares Pharma (ATRS.US)$ +48.7% (to be acquired by Halozyme (HALO) for $5.60 per share)
• $Sierra Oncology (SRRA.US)$ +37.9% (acquired by GSK for $55 per share)
• $Amryt Pharma (AMYT.US)$ +11.7% (announces positive long-term safety and efficacy data for Mycapssa (oral octreotide) from the 2nd Year of OPTIMAL open label extension study in acromegaly patients)
• $BriaCell Therapeutics (BCTX.US)$ +6% (presents development details of...
No comment yet